SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-24-138276
Filing Date
2024-05-14
Accepted
2024-05-14 16:24:19
Documents
60
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q d757777d10q.htm   iXBRL 10-Q 989334
2 EX-31.1 d757777dex311.htm EX-31.1 6601
3 EX-31.2 d757777dex312.htm EX-31.2 6592
4 EX-32.1 d757777dex321.htm EX-32.1 3167
5 EX-32.2 d757777dex322.htm EX-32.2 3158
  Complete submission text file 0001193125-24-138276.txt   4664218

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA vinc-20240331.xsd EX-101.SCH 31411
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE vinc-20240331_cal.xml EX-101.CAL 29869
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vinc-20240331_def.xml EX-101.DEF 187517
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE vinc-20240331_lab.xml EX-101.LAB 316336
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vinc-20240331_pre.xml EX-101.PRE 267939
64 EXTRACTED XBRL INSTANCE DOCUMENT d757777d10q_htm.xml XML 571178
Mailing Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306
Business Address 260 SHERIDAN AVENUE SUITE 400 PALO ALTO CA 94306 650-800-6676
Vincerx Pharma, Inc. (Filer) CIK: 0001796129 (see all company filings)

IRS No.: 833197402 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39244 | Film No.: 24944768
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)